FDA Approves Tesaro’s Drug for Chemotherapy-Induced Nausea

The FDA Sept. 2 approved Tesaro Inc.'s Varubi (rolapitant) to prevent delayed-phase, chemotherapy-induced nausea and vomiting.

Varubi is approved for adults in combination with other drugs that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing cancer chemotherapy, the Food and Drug Administration said. Nausea and vomiting are common side effects experienced by cancer patients undergoing chemotherapy. Symptoms can persist for days after the chemotherapy drugs are administered.

Nausea and vomiting that occurs from 24 hours to 120 hours after the start of chemotherapy is referred to as delayed-phase nausea and vomiting, and it can result in ...